Internat<sub>i</sub> pplication No PCT/GB 03/03669

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K38/08 A61K A61K38/25 A61P9/10 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K A61P C07K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Category \* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X WO OO 23097 A (SAHLTECH AB :ANGELIN BO 1-5 (SE); RUDLING MATS (SE)) 11-16, 27 April 2000 (2000-04-27) 22,26 claims page 4, paragraph 3 X WO 98 22124 A (GENNARO COLONNA VITO DE 1-4, ; BOGHEN MUNY (IT); BERTI FERRUCCIO (IT); 12-15, M) 28 May 1998 (1998-05-28) 22,24-26 claims examples page 26, paragraph 1 X WO OO 67770 A (SAHLTECH AB ; BOLLANO ENTELA (SE); ISGAARD JOERGEN (SE); OMEROVIC E) 1,3,12, 14,15,26 16 November 2000 (2000-11-16) claims -/--X Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: \*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date "L" document which may throw doubts on priority claim(s) or which is clied to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled "O" document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 14 November 2003 28/11/2003 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Böhmerova, E

Internati upplication No PCT/GB 03/03669 Ä

CICantin	inter DOCUMENTS CONSIDERED TO DE TO THE	PC1/GB 03/03669						
Category •	C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT  Category Citation of document, with Indication, where appropriate, of the relevant passages  Relevant to claim No.							
Х	WO 00 09537 A (UNIV TULANE ;BOWERS CYRIL Y (US); LIANG YONGWU (US); MOMANY FRANK) 24 February 2000 (2000-02-24) claims page 24, paragraph 3	1,3,5,6, 12,14, 16,17,26						
X	BROGLIO FABIO ET AL: "Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery" EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 448, no. 2-3, 19 July 2002 (2002-07-19), pages 193-200, XP002261551 ISSN: 0014-2999 abstract page 198, left-hand column, last paragraph	1,3,4, 12,14, 15,26						
X	WALKER RICHARD F ET AL: "Effects of stimulated growth hormone secretion on age-related changes in plasma cholesterol and hepatic low density lipoprotein messenger RNA concentrations" MECHANISMS OF AGEING AND DEVELOPMENT, vol. 75, no. 3, 1994, pages 215-226, XP009021106 ISSN: 0047-6374 abstract; figure 2	1,2,4,5, 11-13, 16,22, 23,26						
X	MARLEAU S ET AL: "Effect of growth hormone releasing peptides (GHRPs) on monocyte/macrophage scavenger receptors (SR) B (CD36) expression and monocyte trafficking" INFLAMMATION RESEARCH, vol. 50, no. Supplement 3, September 2001 (2001-09), page S154 XP009021107 5th World Congress on Inflammation; Edinburgh, Scotland; September 22-26, 2001 ISSN: 1023-3830 abstract	7,10,11, 18,21						
А	BODART V ET AL: "CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart" CIRCULATION RESEARCH, vol. 90, no. 8, 3 May 2002 (2002-05-03), pages 844-849, XP002261552 ISSN: 0009-7330 abstract	7,10,11, 18						

Internation No. PCT/GB 03/03669

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)								
This international Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:								
1. X Claims Nos.:  because they relate to subject matter not required to be searched by this Authority, namely:								
Although claims 1-11 and 23-25 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.								
2. X Claims Nos.: 8,19,23,24 (all partialy) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  see FURTHER INFORMATION sheet PCT/ISA/210								
See FURTHER INFORMATION SHeet PCT/15A/210								
a Claima Man								
3. Claims Nos.:  because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).								
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)								
This International Searching Authority found multiple inventions in this International application, as follows:								
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all								
searchable claims.								
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment								
of any additional fee.								
As solveness of the required additional approx food ways timely said by the applicant this lateractional Sourch Depart								
As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:								
4. No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is								
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:								
Remark on Protest The additional search fees were accompanied by the applicant's protest.								
No protest accompanied the payment of additional search fees.								
protest accompanied the payment of additional search rees.								

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 8,19,23,24 (all partialy)

Present claims 8 and 19 relate to a genes defined by reference to a desirable characteristic or property, namely to genes involved in cellular cholesterol efflux.

The claims cover all genes having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such genes. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the genes LXRalpha and ABCA1 as defined in claims 9 and 20.

Present claims 23 and 24 relate to a compounds defined by reference to a desirable characteristic or property, namely to CD36 ligand. The claims cover all compounds having this characteristic or property, whereas the application does not provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for any such compound. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the GHRPs and derived peptidomimetics.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

Interna Application No PCT/GB 03/03669

	Patent document cited in search report		Publication date	Patent family member(s)			Publication date
WO	0023097	A	27-04-2000	AU AU CA EP JP WO US	2342794	A A1 A1 T A1	28-08-2003 08-05-2000 27-04-2000 22-08-2001 27-08-2002 27-04-2000 06-05-2003
WO	9822124	A	28-05-1998	AU WO	5142498 9822124		10-06-1998 28-05-1998
WO	0067770	A	16-11-2000	AU EP WO	4790800 1173190 0067770	A1	21-11-2000 23-01-2002 16-11-2000
WO	0009537	A	24-02-2000	AU EP JP WO US US	5671099 1159292 2002525265 0009537 2002151501 6468974	A2 T A2 A1	06-03-2000 05-12-2001 13-08-2002 24-02-2000 17-10-2002 22-10-2002